Pooled Saliva Specimens for SARS-CoV-2 Testing
Authors:
- Bidisha BaratBBBidisha Barat
- Sanchita DasSDSanchita Das
- Valeria De GiorgiVGValeria De Giorgi
- David K. HendersonDHDavid K. Henderson
- Stacy KopkaSKStacy Kopka
- Anna Frances LauALAnna Frances Lau
- Tracey MillerTMTracey Miller
- Theresa MoriartyTMTheresa Moriarty
- Tara N. PalmoreTPTara N. Palmore
- Shari SawneySSShari Sawney
- Christine D SpaldingCSChristine D Spalding
- Patricia TanjutcoPTPatricia Tanjutco
Preprint
Abstract
We evaluated saliva (SAL) specimens for SARS-CoV-2 RT-PCR testing by comparison of 459 prospectively paired nasopharyngeal (NP) or mid-turbinate (MT) swabs from 449 individuals with the aim of using saliva for asymptomatic screening. Samples were collected in a drive-through car line for symptomatic individuals (N=380) and in the emergency department (ED) (N=69). The percent positive and negative agreement of saliva compared to nasopharyngeal swab were 81.1% (95% CI: 65.8% – 90.5%) and 99.8% (95% CI: 98.7% – 100%), respectively. The sensitivity increased to 90.0% (95% CI: 74.4% – 96.5%) when considering only samples with moderate to high viral load (Cycle threshold (Ct) for the NP <=34). Pools of five saliva specimens were also evaluated on three platforms: bioMérieux NucliSENS easyMAG with ABI 7500Fast (CDC assay), Hologic Panther Fusion, and Roche COBAS 6800. The median loss of signal upon pooling was 2-4 Ct values across the platforms. The sensitivity of detecting a positive specimen in a pool compared with testing individually was 100%, 93%, and 95% for CDC 2019-nCoV Real-Time RT-PCR, Panther Fusion® SARS-CoV-2 assay, and cobas® SARS-CoV-2 test respectively, with decreased sample detection trending with lower viral load. We conclude that although pooled saliva testing, as collected in this study, is not quite as sensitive as NP/MT testing, saliva testing is adequate to detect individuals with higher viral loads in an asymptomatic screening program, does not require swabs or viral transport media for collection, and may help to improve voluntary screening compliance for those individuals averse to various forms of nasal collections.Keywords
All Related Versions
- Published version: Journal of Clinical Microbiology, 59 (3).
This publication has 28 references indexed in Scilit:
- Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional studyClinical Microbiology and Infection, 2021
- Comparison of SARS-CoV-2 detection in nasopharyngeal swab and salivaJournal of Infection, 2020
- Culture-Based Virus Isolation To Evaluate Potential Infectivity of Clinical Specimens Tested for COVID-19Journal of Clinical Microbiology, 2020
- Saliva as an Alternate Specimen Source for Detection of SARS-CoV-2 in Symptomatic Patients Using Cepheid Xpert Xpress SARS-CoV-2Journal of Clinical Microbiology, 2020
- Saliva as a Noninvasive Specimen for Detection of SARS-CoV-2Journal of Clinical Microbiology, 2020
- Saliva is a reliable tool to detect SARS-CoV-2Journal of Infection, 2020
- Sensitivity of Nasopharyngeal Swabs and Saliva for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2Clinical Infectious Diseases, 2020
- Saliva as a Potential Diagnostic Specimen for COVID-19 TestingJournal of Craniofacial Surgery, 2020
- Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic SamplesClinical Infectious Diseases, 2020
- Saliva is less sensitive than nasopharyngeal swabs for COVID-19 detection in the community settingmedRxiv, 2020